The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-28. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
== Insulin pen == Reith's daughter was diagnosed with Type 1 diabetes when she was four. When her daughter was five, they travelled from Glasgow to London by train as the family relocated to Scotland, and Reith had to use the public toilets at Euston Station to inject her with insulin, a process involving drawing the insulin from a glass phial using a steel hypodermic syringe, which would later require being boiled to re-sterilise it. The inconvenience, discomfort and hygiene implications of this situation led her to conceive a reusable, cartridge-based system. She developed the idea at the Southern General Hospital from 1978 with her colleague and fellow physician John Ireland, and John Paton, a bioengineer recruited at the University of Glasgow's Department of Clinical Physics and Bio-Engineering, for the project. The invention was announced in a January 1981 paper in The Lancet by Reith alongside Ireland, Paton and Margaret Wilson, also of Southern General. It described the use of the prototype, based on a device known as the Becton-Dickinson 'Plastipak' self-contained insulin syringe, by seven patients aged from 8 to 49. Further clinical trials commenced the same year, using 100 pens and 5,000 insulin cartridges funded by Diabetes UK. Within two years the world's first insulin pen, branded "Penject", entered general use.
Cyclin-dependent kinases (CDKs) 4 and 6 are enzymes that have been shown to promote cell division and multiplication in both normal and cancer cells. Many cancer cells have shown abnormalities that increase the activity of CDK, leading to the inactivation of certain tumor suppressor genes. When used in combination with other drugs such as an ALK inhibitor or an MEK inhibitor, ribociclib has been shown to have a synergistic effect, resulting in improved responses. Again, this is likely a result of "crosstalk" between signaling pathways. Simply blocking one pathway in cancer tumorigenesis can sometimes result in "tumor compensation", where the tumor compensates for the blocked signaling pathway by utilizing other pathways to survive. By blocking several pathways at once, it is thought that the tumor is less able to compensate, and a greater anti-tumor response is often observed. Utilizing ribociclib in combination with other agents has been shown to reduce the development of resistance to these agents.
Other investigational drugs using RNAi that are being developed by pharmaceutical companies such as Arrowhead Pharmaceuticals, Dicerna, Alnylam Pharmaceuticals, Amgen, and Sylentis. These medications cover a variety of targets via RNAi and diseases. Investigational RNAi therapeutics in development:
Because of cardiolipin's unique structure, a change in pH and the presence of divalent cations can induce a structural change. CL shows a great variety of forms of aggregates. It is found that in the presence of Ca2+ or other divalent cations, CL can be induced to have a lamellar-to-hexagonal (La-HII) phase transition. And it is believed to have a close connection with membrane fusion.
Sources: en.wikipedia.org
== Origin == The Kalyāṇakāraka, composed in South India by Ugrāditya, is the earliest medical work to contain alchemical content. It is datable to the early ninth century CE. It gives descriptions for the processing of mercury and uses technical terminology related to the procedures and implements required for alchemy. It is the first work to describe purifying (śodhana) and calcining (māraṇaʼ) mercury for medicinal use. The first work of the Sanskrit alchemical literary genre called rasaśāstra is the 10th century Rasahṛdayatantra. The texts 19 chapters focus on the processing mercury, outlines 18 means to process mercury and discusses the transmutation of metals and the body.
== Selected publications == Balalaie, S.; Hashtroudi, M. S.; Arabanian, A. (2000). "One-pot synthesis of tetrasubstituted imidazoles catalyzed by zeolite HY and silica gel under microwave irradiation". Green Chemistry. 2 (6): 274–276. doi:10.1039/b006201o. Balalaie, S.; Bararjanian, M.; Amani, A. M.; Movassagh, B. (2006). "(S)-Proline as a neutral and efficient catalyst for the one-pot synthesis of tetrahydrobenzo [b] pyran derivatives in aqueous media". Synlett. 2006 (2): 263–266. doi:10.1055/s-2005-923606. Bararjanian, M.; Balalaie, S.; Rominger, F.; Movassagh, B.; Bijanzadeh, H. R. (2010). "Six-component reactions for the stereoselective synthesis of 3-arylidene-2-oxindoles via sequential one-pot Ugi/Heck carbocyclization/Sonogashira/nucleophilic addition". The Journal of Organic Chemistry. 75 (9): 2806–2812. doi:10.1021/jo902713x. PMID 20387848. Balalaie, S.; Bararjanian, M.; Hosseini, M.S.; Bigdeli, Z. (2006). "One-pot synthesis of 1,4-dihydropyridine derivatives in a solvent-free condition". Helvetica Chimica Acta. 89 (8): 1769–1773. doi:10.1002/hlca.200690161. Balalaie, S.; Sharafi-Kolkesh, A. (2003). "A novel and efficient one-pot synthesis of 2,4,6-triarylpyridines under solvent-free conditions". Zeitschrift für Naturforschung B. 58 (10): 1075–1077. doi:10.1515/znb-2003-1021.
The colonies of Queensland and South Australia along with the Northern Territory, where three of the four states of colonial Australia which still had large, yet unknown numbers of Aboriginal people living on Country in regional, remote and very remote locations. From time to time, this made in necessary for laws to be created so Australian’s living within the colony understood their responsibilities to society, and the law was working to ensure protection from potential exploitation, perceived or otherwise. By 1897 the passage of law in all three of the above locations had restricted the sale, exchange or trade of opium with any Aboriginal person without exception, this broad application was required to ensure the law was enforceable. Hardening of Canadian attitudes toward Chinese opium users and fear of a spread of the drug into the white population led to the effective criminalization of opium for nonmedical use in Canada between 1908 and the mid-1920s. In 1909, the International Opium Commission was founded, and by 1914, 34 nations had agreed that the production and importation of opium should be diminished. In 1924, 62 nations participated in a meeting of the commission. Subsequently, this role passed to the League of Nations, and all signatory nations agreed to prohibit the import, sale, distribution, export, and use of all narcotic drugs, except for medical and scientific purposes.
Dantrolene sodium, sold under the brand name Dantrium among others, is a postsynaptic muscle relaxant that lessens excitation-contraction coupling in muscle cells. It achieves this by inhibiting Ca2+ ions release from sarcoplasmic reticulum stores by antagonizing ryanodine receptors. It is the primary drug used for the treatment and prevention of malignant hyperthermia, a rare, life-threatening disorder triggered by general anesthesia or drugs. It is also used in the management of neuroleptic malignant syndrome, muscle spasticity (e.g. after strokes, in paraplegia, cerebral palsy, or patients with multiple sclerosis), and poisoning by 2,4-dinitrophenol or by the related compounds dinoseb and dinoterb. The most frequently occurring side effects include drowsiness, dizziness, weakness, general malaise, fatigue, and diarrhea. It is marketed by Par Pharmaceuticals LLC as Dantrium (in North America) and by Norgine BV as Dantrium, Dantamacrin, or Dantrolen (in Europe). A hospital is recommended to keep a minimum stock of 36 dantrolene vials totaling 720 mg, sufficient for a 70-kg person.
This flaw is supported by the FAO/WHO/UNU, who state that BV and NPU are measured when the protein content of the diet is clearly below that of requirement, deliberately done to maximize existing differences in quality as inadequate energy intake lowers the efficiency of protein utilization and in most N balance studies, calorie adequacy is ensured. And because no population derives all of its protein exclusively from a single food, the determination of BV of a single protein is of limited use for application to human protein requirements. Another limitation of the use of Biological Value as a measure of protein quality is that proteins which are completely devoid of one essential amino acid (EAA) can still have a BV of up to 40. This is because of the ability of organisms to conserve and recycle EAAs as an adaptation of inadequate intake of the amino acid. Lastly, the use of rats for the determination of protein quality is not ideal. Rats differ from humans in requirements of essential amino acids. This has led to a general criticism that experiments on rats lead to an over-estimation of the BV of high-quality proteins to man because human requirements of essential amino acids are much lower than those for rats (as rats grow at a much faster rate than humans). Also, because of their fur, rats are assumed to have relatively high requirements of sulphur-containing amino acids (methionine and cysteine). As a result, the analytical method that is universally recognized by the Food and Agriculture Organization (FAO), World Health Organization (WHO), the U.S.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.